With digitalization and globalization, the biomedical industry has become one of the new driving forces of the economy. Especially after the Covid-19 outbreak, the development of the biomedical industry has attracted much attention due to the increased awareness of the crisis and the growing demand for healthcare. China and Japan, as important players in Asia and the world, have made unique contributions to the biomedical industry. Both countries have similarities in aging trends and development potential, but more differences have been shown such as the policy environment and their respective development priorities, which also herald new opportunities and challenges. This paper aims to compare and analyze the status quo, characteristics, and policy environment of the two countries, find out the advantages and disadvantages of each country, analyze the disadvantages and propose reasonable improvement plans. Finally, based on the independent solutions of the two countries, this paper combines the complementary advantages of China and Japan, which is China's high productivity and replication technology with Japan's innovative and management technology, then puts forward a feasible direction for deep cooperation in big data which is of certain guiding significance.
Read full abstract